Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes.

ABSTRACT:

Aims/hypothesis

Lipid abnormalities are associated with diabetic kidney disease and CHD, although their exact role has not yet been fully explained. Sphingomyelin, the predominant sphingolipid in humans, is crucial for intact glomerular and endothelial function. Therefore, the objective of our study was to investigate whether sphingomyelin impacts kidney disease and CHD progression in individuals with type 1 diabetes.

Methods

Individuals (n = 1087) from the Finnish Diabetic Nephropathy (FinnDiane) prospective cohort study with serum sphingomyelin measured using a proton NMR metabolomics platform were included. Kidney disease progression was defined as change in eGFR or albuminuria stratum. Data on incident end-stage renal disease (ESRD) and CHD were retrieved from national r

SUBMITTER: Pongrac Barlovic D 

PROVIDER: S-EPMC7406485 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature